CellBion Co., Ltd. (KOSDAQ:308430)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,100
-300 (-1.18%)
At close: Aug 12, 2025, 3:30 PM KST
-1.18%
Market Cap 359.50B
Revenue (ttm) 2.57B
Net Income (ttm) -7.30B
Shares Out 12.82M
EPS (ttm) -570.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 133,303
Average Volume 267,917
Open 25,450
Previous Close 25,400
Day's Range 25,000 - 26,150
52-Week Range 9,930 - 29,600
Beta n/a
RSI 62.48
Earnings Date n/a

About CellBion

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphos... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 308430
Full Company Profile

Financial Performance

In 2024, CellBion's revenue was 2.29 billion, an increase of 55.64% compared to the previous year's 1.47 billion. Losses were -7.27 billion, 100.0% more than in 2023.

Financial Statements

News

There is no news available yet.